US and China agree to a tactical trade truce, suspending port fees and reducing some tariffs, but key issues remain unresolved.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
US and China agree to a one-year trade truce, pausing tariff threats and easing export controls, but core disputes remain unresolved.
US and China agree to a tactical trade truce, suspending port fees and reducing some tariffs, but key issues remain unresolved.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
US and China agree to a one-year trade truce, pausing tariff threats and easing export controls, but core disputes remain unresolved.